FcγRIIb inhibition promotes the overproduction of pro-inflammatory cytokines, including TNF-α which is active in inflammatory diseases, including Grave’s disease, rheumatoid arthritis, periodontitis and SLE [28]. Here, FCGR2B is linked to systemic lupus erythematosus.